BACKGROUND: Herpes virus infections may have a significant role in chronic lymphocytic leukaemia (CLL) due to their ability to modulate the host's immune system. MATERIALS AND METHODS: We examined the seroprevalence of four herpes viruses [Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), human herpes virus (HHV)-6 and -7] in a cohort of European CLL patients (cohort 1, n = 100) in relation to the immunoglobulin variable heavy (IGHV) chain gene use and compared serological results with those obtained from age- and gender-matched healthy adults (n = 100). RESULTS: CMV-seroprevalence was significantly higher in CLL cohort 1 (79%) than in the control cohort (57%, P = 0.001); the seroprevalence of EBV (89% vs. 94%), HHV-6 (73% vs. 60%), or HHV-7 (35% vs. 35%) was not. In CLL cohort 1, use of IGHV3-30 was more prevalent among CMV-seropositive and of IGHV3-21 among HHV-7-seronegative cases. To investigate the generalizability of these findings, we investigated the herpes virus seroprevalence in a second cohort of age-matched CLL patients from a different geographical area (USA, n = 100, cohort 2). In cohort 2, CMV-seroprevalence was comparable with that of the control cohort (53%). Seroprevalence of EBV, HHV-6 and HHV-7 were 85%, 88% and 73% respectively. In CLL cohort 2, use of IGHV3-30 or IGHV3-21 was not associated with any of the herpes viruses investigated. CONCLUSIONS: CMV-seropositivity is associated with CLL in selected patient cohorts. However, the considerable variation in herpes virus-specific seropositivity between geographically distinct CLL cohorts indicates that seropositivity for any of the four human herpes viruses investigated is not generally associated with CLL.
BACKGROUND: Herpes virus infections may have a significant role in chronic lymphocytic leukaemia (CLL) due to their ability to modulate the host's immune system. MATERIALS AND METHODS: We examined the seroprevalence of four herpes viruses [Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), human herpes virus (HHV)-6 and -7] in a cohort of European CLL patients (cohort 1, n = 100) in relation to the immunoglobulin variable heavy (IGHV) chain gene use and compared serological results with those obtained from age- and gender-matched healthy adults (n = 100). RESULTS: CMV-seroprevalence was significantly higher in CLL cohort 1 (79%) than in the control cohort (57%, P = 0.001); the seroprevalence of EBV (89% vs. 94%), HHV-6 (73% vs. 60%), or HHV-7 (35% vs. 35%) was not. In CLL cohort 1, use of IGHV3-30 was more prevalent among CMV-seropositive and of IGHV3-21 among HHV-7-seronegative cases. To investigate the generalizability of these findings, we investigated the herpes virus seroprevalence in a second cohort of age-matched CLL patients from a different geographical area (USA, n = 100, cohort 2). In cohort 2, CMV-seroprevalence was comparable with that of the control cohort (53%). Seroprevalence of EBV, HHV-6 and HHV-7 were 85%, 88% and 73% respectively. In CLL cohort 2, use of IGHV3-30 or IGHV3-21 was not associated with any of the herpes viruses investigated. CONCLUSIONS: CMV-seropositivity is associated with CLL in selected patient cohorts. However, the considerable variation in herpes virus-specific seropositivity between geographically distinct CLL cohorts indicates that seropositivity for any of the four human herpes viruses investigated is not generally associated with CLL.
Authors: Marianne C Morris; W John Edmunds; Louise M Hesketh; Andrew J Vyse; Elizabeth Miller; Peter Morgan-Capner; David W G Brown Journal: J Med Virol Date: 2002-08 Impact factor: 2.327
Authors: Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-06-24 Impact factor: 22.113
Authors: Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai Journal: Blood Date: 2002-05-15 Impact factor: 22.113
Authors: E Kostareli; A Hadzidimitriou; N Stavroyianni; N Darzentas; A Athanasiadou; M Gounari; V Bikos; A Agathagelidis; T Touloumenidou; I Zorbas; A Kouvatsi; N Laoutaris; A Fassas; A Anagnostopoulos; C Belessi; K Stamatopoulos Journal: Leukemia Date: 2009-01-15 Impact factor: 11.528
Authors: Paul D Ling; John A Lednicky; Wendy A Keitel; David G Poston; Zoe S White; RongSheng Peng; Zhensheng Liu; Satish K Mehta; Duane L Pierson; Cliona M Rooney; Regis A Vilchez; E O'Brian Smith; Janet S Butel Journal: J Infect Dis Date: 2003-04-30 Impact factor: 5.226
Authors: M E Guinan; P A Thomas; P F Pinsky; J T Goodrich; R M Selik; H W Jaffe; H W Haverkos; G Noble; J W Curran Journal: Ann Intern Med Date: 1984-02 Impact factor: 25.391
Authors: Christoph Steininger; George F Widhopf; Emanuela M Ghia; Christopher S Morello; Katrina Vanura; Rebecca Sanders; Deborah Spector; Don Guiney; Ulrich Jäger; Thomas J Kipps Journal: Blood Date: 2012-01-10 Impact factor: 22.113
Authors: C Quadrelli; P Barozzi; G Riva; D Vallerini; E Zanetti; L Potenza; F Forghieri; M Luppi Journal: Mediterr J Hematol Infect Dis Date: 2011-10-24 Impact factor: 2.576
Authors: Eva Eliassen; Emily Lum; Joshua Pritchett; Joseph Ongradi; Gerhard Krueger; John R Crawford; Tuan L Phan; Dharam Ablashi; Stanley David Hudnall Journal: Front Oncol Date: 2018-11-13 Impact factor: 6.244
Authors: Nereida Jiménez de Oya; Marco De Giovanni; Jessica Fioravanti; Rudolf Übelhart; Pietro Di Lucia; Amleto Fiocchi; Stefano Iacovelli; Dimitar G Efremov; Federico Caligaris-Cappio; Hassan Jumaa; Paolo Ghia; Luca G Guidotti; Matteo Iannacone Journal: EMBO Mol Med Date: 2017-11 Impact factor: 12.137